Mycobacterium Bovis Bcg
Mycobacterium Bovis Bcg - Related Videos
04:06
Preparation and Quantification of Mycobacterium bovis BCG lux Inoculum for Infection
0 Views •
2025
This video demonstrates the preparation and quantification of Mycobacterium bovis Bacillus Calmette-Guérin lux inoculum using bioluminescence assay and the enumeration of colony-forming units. The prepared inoculum can be used for infection studies.
03:12
An Avidin-Biotin Conjugation Technique for Presenting Target Antigens on Mycobacterium bovis BCG
0 Views •
2025
The video demonstrates a technique for loading antigens on Mycobacterium bovis BCG to improve its immunogenic properties. The method uses the avidin-biotin system to coat the bacterial surface with exogenous antigens.
02:16
Intranasal Immunization with BCG in a Mouse Model
0 Views •
2025
This video demonstrates intranasal BCG immunization in mice, activating both innate and adaptive immune responses, leading to the development of lung-resident memory T cells and effector B cells, thus enhancing protection against Mycobacterium infections.
10:11
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
0 Views •
2018
A novel technique for rapid antigen display on a bacterial surface is presented, which involves surface biotinylation followed by exposure to proteins of interest in fusion with monomeric avidin. Loading BCG with selected antigens successfully improves its immunogenicity, suggesting that surface decoration can replace traditional genetic approaches.
07:14
A CFSE-based Assay to Study the Migration of Murine Skin Dendritic Cells into Draining Lymph Nodes During Infection with Mycobacterium bovis Bacille Calmette-Guérin
0 Views •
Cited by 10 •
2016
An assay in mice to track cell migration from skin to draining lymph node is described which enables the characterization of skin Dendritic cells mobilized to the lymph node after footpad infection with Bacille Calmette-Guérin.
FAQs
Recognition by pathogen-sensing receptors provides an early signal that BCG is present. This sensing activates innate immune cells and promotes cytokine release, creating conditions that recruit and stimulate additional immune cells. In immunology research, this receptor-driven initiation helps explain how a live attenuated strain can produce broader immune activation rather than functioning only as a passive source of microbial antigens.
These components contribute at different stages of the response. Cytokines act as signaling molecules that coordinate inflammation, macrophages become activated as part of the innate response, and recruited lymphocytes strengthen subsequent local and systemic immunity. Studying their combined activity shows how early innate recognition can be connected to a more extensive immune response relevant to infection and immunotherapy.
The same immunomodulatory capacity is applied in two distinct settings. During tuberculosis prevention, immune activation helps limit disease caused by Mycobacterium tuberculosis, with particular importance for severe childhood forms. In bladder cancer treatment, the desired outcome is local inflammation in the bladder that contributes to tumor-cell elimination. The biological context therefore determines how the response is interpreted.
Because BCG is live but attenuated, it can engage host immune defenses while serving as a vaccine strain rather than the disease-causing tuberculosis organism described in the overview. This property makes it useful for examining host-pathogen interactions, immune activation, and immunomodulation. Its use across prevention and cancer treatment also allows investigators to compare immune outcomes in different tissues.
For non-muscle-invasive bladder cancer, BCG is administered intravesically, meaning the treatment is delivered into the bladder. The intended effect is stimulation of inflammation within that organ, where the resulting immune activity can help eliminate tumor cells. This localized application provides a clear model for investigating how microbial immune signals can be directed toward a cancer-treatment outcome.
BCG is used primarily for tuberculosis prevention. Its administration activates innate immune cells, induces cytokine release, and recruits lymphocytes, producing local and systemic immune responses that help limit disease caused by Mycobacterium tuberculosis. The protection is especially relevant to severe childhood forms of tuberculosis, making BCG an important subject for studying vaccination within infectious-disease immunology.
BCG supports research on how pathogen-sensing receptors initiate immune signaling, how cytokines coordinate macrophage activation and lymphocyte recruitment, and how inflammation produces different outcomes in infection prevention versus cancer treatment. Its use in both tuberculosis vaccination and bladder cancer immunotherapy makes it a useful comparative system for examining immune responses across distinct clinical and tissue contexts.